Home » QUINTILES ENTERS PACT ON DRUG
QUINTILES ENTERS PACT ON DRUG
Quintiles Transnational will provide a Seattle-based biotechnology firm with $30 million in cash and services in return for at least $53 million in royalties. The Durham contract research organization announced the six-year pact between its PharmaBio Development arm and Cell Therapeutics. In it, Quintiles will pay CTI $25 million in cash and provide $5 million worth of clinical services.
The Herald-Sun (http://www.herald-sun.com/business/21-559668.html)
KEYWORDS FDAnews Drug Daily Bulletin
Upcoming Events
-
25Apr
-
07May
-
14May
-
30May